Top of this page
Skip navigation, go straight to the content

Our Company Key facts

Key facts

picture of a tablet
  • A global biopharma focused on severe diseases in two therapeutic areas: neurology and immunology
  • Global revenue of € 4.6 billion in 2018
  • Operations in approximately 40 countries, supported by around 7,500 people
  • Established in 1928, successful transformation from a hybrid specialty chemical company into a patient-centric biopharma company
  • Listed on the Euronext Brussels Stock Exchange
  • Headquartered in Brussels, Belgium.

Financials

Revenue - A 5-year overview

Graphic revenue 5-year overview

Sales

Therapeutic areas

Focusing on severe diseases, UCB develops and markets human pharmaceutical products in two core therapeutic areas:

  • Neurology: epilepsy, Parkinson's disease, restless legs syndrome,...
  • Immunology: rheumatoid arthritis, psoriasis, psoriatic arthritis, axial spondyloarthritis, Crohn's disease, bone health,...
 

Net sales by therapeutic area

 

 

Net sales by region

 

 
 

Top selling products

€ million Actual
2014
Actual
2015
Actual
2016
Actual
2017
Actual
2018

Core products

Cimzia®7971083130714241446
Vimpat®4716798149761099
Keppra®665737724778790
Neupro®200258302314321
Briviact®  1887142

Other products

Zyrtec® 163147140103101
Xyzal®9611710710490
 

Our people - Employees by region